$0.28
4.94%
Nasdaq, Nov 19, 03:57 pm EST. Closed.
ISIN
US5894921072
Symbol
MREO

Mereo BioPharma Group plc Sponsored ADR Stock News

Neutral
●
GlobeNewsWire
●
11 days ago
Ongoing regulatory interactions in collaboration with Ultragenyx on potential path forward for setrusumab in osteogenesis imperfecta (OI) Ongoing FDA interactions in collaboration with Sentynl Therapeutics to refine Phase 3 trial design for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) Cash and cash equivalents of $26.1 million at September 30, 2026, expected to...
Neutral
●
PRNewsWire
●
3 months ago
Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and retains rest of the world rights Mereo will receive an upfront option fee and, on option exercise, is eligible to receive up ...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today